NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Steve Darling from Proactive to share news to discuss the significant antiviral capabilities of NV-387. The company reports that NV-387 exhibits ultra-broad antiviral activity. NV-387's spectrum extends beyond combating COVID-19 and corona viruses to RSV and Influenza A viruses, including potentially the Bird Flu H5N1 virus. In comparative studies against approved anti-influenza drugs—Oseltamivir, Peramivir, and Baloxivir—NV-387 demonstrated superior antiviral effects. In a lethal lung infection model with the H3N2 strain, NV-387 treated mice showed a remarkable survival rate, significantly outperforming the traditional treatments and highlighting its potential as a more effective antiviral agent.
NV-387 has also shown ffectiveness against the orthopoxvirus family through both inhalation and skin abrasion modes of infection acquisition. Notably, Ectromelia virus infection in mice, which is a model for Smallpox in humans and serves as a surrogate for MPox infection, has been successfully countered by NV-387. In a lethal animal model of lung infection by Ectromelia virus, oral administration of NV-387 significantly increased the lifespan of mice, showing comparable results to those treated with tecovirimat, the approved Smallpox drug. This positions NV-387 as a strong clinical candidate for treating poxvirus infections under the US FDA "Animal Rule." Additionally, combining NV-387 with tecovirimat may further enhance its effectiveness by reducing the potential for resistance development.
This array of successful outcomes underscores NanoViricides' commitment to advancing antiviral therapy and enhancing public health defenses against a range of viral threats.